Difference between revisions of "Workshop on Clinical Trial Ontology"
Line 39: | Line 39: | ||
Russ Altman -- Stanford University | Russ Altman -- Stanford University | ||
+ | |||
+ | Carol Bean -- NCRR/NIH | ||
Werner Ceusters -- NCBO, University at Buffalo | Werner Ceusters -- NCBO, University at Buffalo | ||
Lindsay Cowell -- Duke University | Lindsay Cowell -- Duke University | ||
+ | |||
+ | Peter Good -- NHGRI/NIH | ||
Norbert Graf -- [http://acgt.ercim.org/ ACGT], Homburg, Germany | Norbert Graf -- [http://acgt.ercim.org/ ACGT], Homburg, Germany | ||
Ted Grasela -- Cognigen Corporation, Amherst, NY | Ted Grasela -- Cognigen Corporation, Amherst, NY | ||
+ | |||
+ | Chris Mungall -- Howard Hughes Institute | ||
Mark Musen -- NCBO, Stanford University | Mark Musen -- NCBO, Stanford University | ||
Line 66: | Line 72: | ||
CDISC: Becky Kush | CDISC: Becky Kush | ||
HL7: Lakshmi Grama | HL7: Lakshmi Grama | ||
− | caBIG: | + | caBIG: ? |
− | NIH Roadmap: Stuart Speedie (U. Minn) | + | NIH Roadmap: Stuart Speedie (U. Minn) ? |
AMIA CT WG: Michael Kahn, Charlie Barr, | AMIA CT WG: Michael Kahn, Charlie Barr, | ||
AMIA KR WG: not sure who | AMIA KR WG: not sure who |
Revision as of 05:48, 19 June 2006
General Information
The National Center for Biomedical Ontology will host a two-day workshop focused on the Ontology of Clinical Trials. The workshop will take place in March 2007; venue to be determined.
Aim of the workshop
The aim of the workshop is to foster the creation of a reference ontology (high-quality controlled structured vocabulary) for clinical trial annotation. The ontology should provide a definitions for terms like: cohort, randomization, placebo, response, efficacy, control, protocol, null hypothesis, control, confidence intervals, etc., including also major relevant statistical terms.
The proposed CTO should:
(1) fully and faithfully capture the types of entities and relationships involved in clinical trials of any experimental design
(2) comprehend all the terms needed for the task of meta-analysis of clinical trials
(3) support trial bank interoperation
(4) form an integral part of a more comprehensive investigation ontology, including also the Functional Genomics Investigation Ontology, which should form part of the OBO Foundry.
The purpose of the meeting is to bring together representatives of the major groups involved in clinical trial informatics, design, execution, analysis and standardization in order to approve an initial draft of the CTO and create a strategy for its further development and testing.
Further topics to be addressed include:
i. The relation between CTO and data-model-oriented initiatives (HL7, CDISC, BRIDG, caBIG).
ii. The relation between CTO and a drug (trial) ontology
iii. The relation between CTO and an epidemiology study ontology
iv. The proper treatment of types (surgical intervention, tumor, human being) and instances (Jane's oophorectomy, John's tumor, Fritz) in ontologies and related artifacts.
v. The relation between CTO, Trialbank, and OBD.
Agenda
Participation
Requests for participation are welcome. Please send a brief statement of your expertise to Barry Smith.
Participants (First Tentative List)
Russ Altman -- Stanford University
Carol Bean -- NCRR/NIH
Werner Ceusters -- NCBO, University at Buffalo
Lindsay Cowell -- Duke University
Peter Good -- NHGRI/NIH
Norbert Graf -- ACGT, Homburg, Germany
Ted Grasela -- Cognigen Corporation, Amherst, NY
Chris Mungall -- Howard Hughes Institute
Mark Musen -- NCBO, Stanford University
Fabian Neuhaus -– NCBO, University at Buffalo
Ricardo Pietrobon -- Duke University
Nigam Shah -– NCBO, Stanford Medical Informatics
Susanna Sansone -- EBI, Hinxton, Cambridge
Ida Sim -- NCBO, University of San Francisco Medical Center
Barry Smith -– NCBO, University at Buffalo
Still more tentative: BRIDG: Doug Fridsma, Joyce Niland (maybe) CDISC: Becky Kush HL7: Lakshmi Grama caBIG: ? NIH Roadmap: Stuart Speedie (U. Minn) ? AMIA CT WG: Michael Kahn, Charlie Barr, AMIA KR WG: not sure who Columbia group on Clinical Trials Informatics